DEA Temporarily Schedules 7-Hydroxymitragynine and Three Synthetic Derivatives as Schedule I

Why it matters

The DEA action is the most significant federal regulatory move on kratom in nearly a decade, targeting the most potent and commercially prevalent extracts while explicitly preserving the legal status of traditional botanical kratom — a distinction that will reshape how the industry operates.

The big picture

The DEA's announcement represents a targeted regulatory approach: classify the highly concentrated synthetic derivatives that have fueled harm, while leaving unaltered botanical kratom untouched. This mirrors the framework regulators have used with synthetic cannabinoids and fentanyl analogues. 7-OH occurs naturally in kratom leaves but represents less than 2% of the plant's alkaloid content; commercial 7-OH products are typically manufactured or concentrated far beyond natural levels. The scheduling action cites an imminent public health threat, citing the ready availability of these products in convenience stores, smoke shops, and online marketplaces.

Key findings

• DEA announced temporary Schedule I placement of 7-hydroxymitragynine (7-OH) and three synthetic derivatives: mitragynine pseudoindoxyl (MP), dihydro-7-hydroxymitragynine (MGM-15), and 9-fluoro-dihydro-7-hydroxymitragynine (MGM-16)
• 7-OH in its natural form represents less than 2% of kratom's alkaloid content; commercial products often contain far higher concentrations
• The scheduling action does NOT affect unscheduled botanical kratom
• Thresholds: kratom plant material must contain ≤0.05% 7-OH to remain unscheduled; processed extracts face a 0.05% or 1mg per serving threshold
• The action is described as targeting growing public health threats from products widely available in convenience stores, smoke shops, and online

What they say

The DEA stated the temporary scheduling is intended to address "an imminent hazard to public safety" from concentrated 7-OH products increasingly available outside traditional retail controls.

Bottom line

The DEA's July 2026 action places concentrated 7-OH and three synthetic analogues into Schedule I while explicitly leaving botanical kratom untouched — a first federal step to differentiate natural plant products from potent synthetic extracts.